Gallium-68 PSMA vs. fluorine-18 fluciclovine PET/CT scans

According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy. … READ MORE …

Early data suggest 18F-DCFPyL PET/CT scans can change patient management

A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …

How to get a free gallium-68 PSMA-11 PET/CT scan (and yes, there IS a catch)

A research team at the University of California, Los Angeles (UCLA) is seeking participants for a randomized, Phase III, clinical trial of the utility of 68Ga-PSMA-11 PET/CT molecular imaging for planning of salvage radiotherapy after first-line treatment for localized prostate cancer. … READ MORE …

Gallium-68 PSMA PET scanning “is a game changer” in prostate cancer

The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer. … READ MORE …

Progenics reports outcome of OSPREY 2301 trial of PyL™

In a media release issued earlier this morning, Progenics Pharmaceuticals has announced the outcome of a Phase II/III trial of their proprietary, PSMA-targeted imaging agent PyL (also known as 18F-DCFPyL) for identification of prostate cancer. … READ MORE …

Gallium-68 PET/CT scans prior to first-line treatment of some men with prostate cancer

A newly-reported set of data from an Australian clinical research team has now shown that 68Ga PSMA PET/CT scans changed the staging and the management of men after initial diagnosis and prior to first-line treatment compared to traditional CT and bone scanning. … READ MORE …

Free randomized clinical trial of gallium-68-PSMA-11 PET indicator

A randomized clinical trial of the 68Ga-PSMA-11 PET indicator for men with a recurrence after radical prostatectomy has just been initiated at the University of California Los Angeles (UCLA). … READ MORE …

A PSMA-based PET scan can change SRT decisions

The new PSMA-based PET scans provide a way to locate exactly where the cancer has spread to after an unsuccessful prostatectomy. … READ MORE …

Radio-guided surgery in the treatment of recurrent, initially localized prostate cancer

The re-treatment of patients with recurrent prostate cancer after initial, first-line treatment for what was initially diagnosed as localized disease can be complicated. Success (i.e., effective re-treatment with curative intent) in the re-treatment of such patients is often dependent on the ability to identify exactly where recurrence has occurred. … READ MORE …

Axumin PET/CT scans change treatment recommendations in recurrent prostate cancer

The value of many cancer-related tests is actually based on whether the results of the particular test change the way that  physicians plan to treat specific patients (hopefully for the better). … READ MORE …

Axumin-enhanced PET scans becoming more widely available

Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …

Yet another new PMSA-linked radioisotope enters clinical trials in prostate cancer

As many readers will be aware, there has been a lot of ongoing research using the gallium-68 (68Ga) radioisotope linked to various forms of prostate-specific membrane antigen (PSMA) in concert with PET scan imaging to identify sites of early recurrence of prostate cancer. … READ MORE …

Increasing availability of the Axumin-enhanced PET scan

Back in May this year we reported that the US Food and Drug Administration had approved a new type of imaging agent known as [18F]fluciclovine (Axumin®) for use in association with PET scans in men with recurrent prostate cancer that might have spread to other parts of the body, but which was not evident on older forms of scan. … READ MORE …

Can PSMA PET scans replace the need for bone and CT scans?

A new review article suggests the possibility that radiolabeled prostate specific membrane antigens (PSMAs) and PET scans may, at some point in the not too distant future, replace bone and CT scans in diagnosis and monitoring of men with advanced forms of prostate cancer. … READ MORE …

Is this new form of PET scan perhaps too good at detecting prostate cancer?

A newly reported pilot study in the Journal of Urology has suggested that a new form of PET scan may be “much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today.” … READ MORE …